News Image

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Provided By GlobeNewswire

Last update: Aug 10, 2023

OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company’s progress.

Read more at globenewswire.com
Follow ChartMill for more